The White House estimates that President Donald Trump’s negotiated deals with pharmaceutical companies could save the U.S. economy $529 billion over the next decade by requiring some U.S. prescription drug prices to fall toward levels the companies charge in other countries, according to multiple reports. ABC News and MedPage Today both describe the estimate as coming from White House economists and tied to the administration’s framework for lowering certain drug prices. Courthouse News adds context by noting that outside economists question whether projected savings would translate directly into lower costs for patients. It points out that many insured patients already pay discounted rates through their insurance plans, which could limit how much of any macroeconomic savings is felt at the consumer level. Breitbart similarly reports the release of a White House report estimating the $529 billion savings over ten years, aligning with the figures cited by other outlets. Across coverage, the key points are the claimed $529 billion estimate from the White House, its basis in reducing some U.S. drug prices, and the uncertainty raised by external analysts about how savings would distribute between payers and patients.